SCYNEXIS, Inc. (0L49)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 3.680 |
|---|---|
| 52-week range | 0.568 – 6.490 |
| Return, 1 month / 3 months | −22.4% / −20.2% |
| Return, 1 year / 3 years | +371.6% / +103.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 33 |
| Volatility (1 year) | 217.7% |
| Worst drawdown (1 year) | -40.7% |
| Average daily value traded | 0.02M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
SCYNEXIS, Inc. is a pharmaceutical company that develops antifungal medicines. Its main product is an oral treatment for vaginal yeast infections, and it also works on antifungal therapies for other serious fungal conditions. The company serves patients and healthcare providers through prescription medicines, and it is based in the United States. Its work centres on drug discovery and clinical development of compounds that address fungal disease.
The shares are listed on the London Exchange in UK under the code 0L49, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
SCYNEXIS, Inc. (0L49) trades on the London Exchange in UK. It last closed at USD 3.680 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,291 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 371.6% and over the last three months it fell 20.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 35.2% | ||
| From 52-week high | -38.7% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -20.2% | ||
| 6-month return | 260.8% | ||
| 12-month return, skipping the last month | 507.5% | ||
| Stability (higher is calmer) | 16 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 217.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.7% | ||
| Liquidity | 12 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M USD | ||
| Zero-volume days | 36.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.6% |
|---|---|
| 1 month | −22.4% |
| 3 months | −20.2% |
| 6 months | +260.8% |
| 1 year | +371.6% |
| 3 years | +103.3% |
| 5 years | −30.4% |
Signals
| 50-day / 200-day average | 4.583 / 2.722 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.276 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.